Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.37 |
| ▸ | GSR | P00390 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665710 | 1.00 | TSHR (0.43) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL3294386 | 0.84 | TSHR (0.46) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL3144065 | 0.77 | LMNA (0.41) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL11817568 | 0.75 | TSHR (0.50) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL16289365 | 0.74 | LMNA (0.38) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL31511551 | 0.74 | TSHR (0.38) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL18387601 | 0.74 | LMNA (0.38) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL30945318 | 0.74 | ALDH1A1 (0.49) | TSHRTDP1ALDH1A1LMNAKMT2A | |
| SCHEMBL4494414 | 0.74 | LMNA (0.38) | TSHRCYP3A4TDP1ALDH1A1LMNA | |
| SCHEMBL188183 | 0.74 | TSHR (0.38) | TSHRCYP3A4TDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4709373-A2 | HETEROCYCLIC COMPOUNDS FOR IMAGING AGGREGATED TAU IN TAUOPATHIES | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4652159-A1 | INHIBITORS OF KIF18A AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250289803-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | SENTONIX INC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4612139-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | Sentonix, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-6864261-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-03-08 | — | — | US | disclosed |
| EP-1214296-B1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| US-6689909-B1 | TREATMENT OF DISEASE STATE SELECTED FROM THE GROUP CONSISTING OF DIABETES MELLITUS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL ISCHAEMIA | ASTRAZENECA AB (SE) | 2004-02-10 | — | — | US | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| EP-1348698-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| CN-1387509-A | Substd. N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. which elevate pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-25 | — | — | CN | disclosed |
| EP-1214296-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017956-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |
| EP-0385850-A2 | Benzimidazole and azabenzimidazole derivatives, process for their preparation, synthesis intermediates, pharmaceutical compositions containing them, useful for the treatment of cardiovascular diseases and duodenal ulcers | LABORATOIRES UPSA (FR) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | TSHR 2139/4885CYP3A4 4358/4885TDP1 997/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | TSHR 1125/4885CYP3A4 4635/4885TDP1 757/4885 |
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF2C | TSHR 4396/4885CYP3A4 4792/4885TDP1 213/4885 |
| US-20250289803-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | MAPT, PSEN1, PSEN2 | TSHR 391/4885CYP3A4 4080/4885TDP1 257/4885 |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | TSHR 3109/4885CYP3A4 4435/4885TDP1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.